Ingevity (NYSE:NGVT) CEO Sells $379,150.00 in Stock

Ingevity Corporation (NYSE:NGVT) CEO David Li sold 5,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $75.83, for a total transaction of $379,150.00. Following the completion of the sale, the chief executive officer owned 120,636 shares in the company, valued at approximately $9,147,827.88. This trade represents a 3.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingevity Stock Down 2.3%

NYSE:NGVT opened at $69.54 on Friday. The company has a market capitalization of $2.39 billion, a price-to-earnings ratio of 47.31 and a beta of 1.16. Ingevity Corporation has a one year low of $45.85 and a one year high of $79.29. The stock has a 50-day simple moving average of $73.88 and a 200 day simple moving average of $71.84. The company has a debt-to-equity ratio of 22.52, a quick ratio of 1.15 and a current ratio of 1.61.

Ingevity (NYSE:NGVT) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.41. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.The firm had revenue of $314.10 million for the quarter, compared to analysts’ expectations of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Sell-side analysts predict that Ingevity Corporation will post 5.4 EPS for the current fiscal year.

Institutional Trading of Ingevity

Several hedge funds have recently made changes to their positions in NGVT. Global Retirement Partners LLC bought a new position in Ingevity during the 4th quarter worth $27,000. Meeder Asset Management Inc. acquired a new position in shares of Ingevity during the fourth quarter valued at $33,000. Geneos Wealth Management Inc. increased its stake in Ingevity by 85.8% during the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after buying an additional 387 shares during the period. Frazier Financial Advisors LLC acquired a new position in shares of Ingevity during the second quarter valued at approximately $37,000. Finally, Headlands Technologies LLC bought a new stake in shares of Ingevity in the 2nd quarter worth $46,000. Institutional investors own 91.59% of the company’s stock.

Wall Street Analyst Weigh In

NGVT has been the topic of several research analyst reports. Weiss Ratings upgraded Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Wall Street Zen cut shares of Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Ingevity presently has an average rating of “Hold” and a consensus target price of $80.00.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.